Tirzepatide vs Liraglutide in Bone

Launched by NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS · Jul 28, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how two different medications, tirzepatide and liraglutide, affect bone health and body composition in adults with severe obesity (a Body Mass Index, or BMI, of 40 or higher). The researchers want to see how these medications influence markers that show bone breakdown, as well as changes in weight, body fat, and bone density over six months. The main focus is on a specific bone marker measured after three months to understand if one medication might be better or safer for bones during weight loss.

Adults between the ages of 30 and 65 with a BMI of 40 or higher may be eligible to join, but people with diabetes, kidney or liver problems, heart failure, cancer, recent fractures, pregnancy, or certain bone and hormonal conditions cannot participate. The study involves visits at the start, three months, and six months, where participants will have tests to check their bones and body composition. This trial is important because it will help doctors understand how these weight-loss medicines might affect bone health, which is especially valuable for people with severe obesity considering treatment options.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults aged between 30 and 65 years
• • BMI ≥40 kg/m²
• Exclusion Criteria:
• • Type 2 Diabetes Mellitus (T2DM) and type 1 Diabetes Mellitus (T1DM)
• • Chronic kidney disease
• • Liver failure
• • Heart failure
• • Malignancy coexistence
• • Previous bariatric or gastrointestinal surgery involving intestinal bypass
• • Uncontrolled hypo/hyperthyroidism
• • Uncontrolled hypo/hyperparathyroidism
• • Pregnancy and lactation
• • Recent fracture (within 2 years)
• • Rare Metabolic Bone Diseases (e.g., Paget's disease of bone, fibrous dysplasia, osteopetrosis)
• • Inflammatory arthritis
• • Medications which can affect bone markers: bone-anabolic agents, antiresorptive agents, antiandrogenic agents, vitamin K antagonists, antipsychotic agents, contraceptives, glucocorticoids (oral), methotrexate, thiazides, aromatase inhibitors etc)
• • Hemolytic anemia